Skip to main content
Terug
Watch Compare

Nuvectis Pharma, Inc.

Datakwaliteit: 83%
NVCT
NASDAQ Manufacturing Chemicals
€ 8,50
▼ € 0,23 (-2,63%)
6 months return
—
Momentum
Neutral
ROE
-129,36%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-129,36%
Onder sectorgemiddelde (-54,47%)
ROIC-106,57%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio3,07
Interest CoverageN/A

Waardering

PE (TTM)
-8,18
Onder sectorgemiddelde (-1,50)
P/B Ratio9,00
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -16,01 M

Price History

Financiële Trends

Koersdoel Analisten

5 analisten
Buy
+97.6%
upside to target
Huidig
€ 8,50
Consensus Target
€ 16,80
€ 10,00
Laag
€ 20,00
Hoog
Vooruitzicht
Forward WPA
-€ 1,32
Omzet Sch.
0,0

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 0,31 · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 0,27 -€ 0,30 -€ 0,44 -€ 0,31 — —
Estimate -€ 0,25 -€ 0,25 -€ 0,25 -€ 0,31 -€ 0,31 -€ 0,32
Verrassing -6,30% -19,20% -76,00% -0,65% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -129,36% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -26,44 M
ROE -129,36% ROA -84,49%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -16,01 M
ROIC -106,57% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 3,07
Debt / Equity N/A Current Ratio 3,07
Interest Coverage N/A Asset Turnover N/A
Working Capital 24,01 M Tangible Book Value 24,01 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -8,18 · EV/EBITDA: N/A
P/E Ratio -8,18 Forward P/E N/A
P/B Ratio 9,00 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -7,41%
Market Cap 216,17 M Enterprise Value 180,73 M

Per Share

EPS: -1,32 · FCF/Share: -0,60
EPS (Diluted TTM) -1,32 Revenue / Share N/A
FCF / Share -0,60 OCF / Share -0,60
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 60,54% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 60,54%
SBC-Adj. FCF -21,83 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue — — — —
Net Income -26,44 M -19,00 M -22,26 M -19,09 M
EPS (Diluted) -1,32 -1,11 -1,43 -1,51
Gross Profit — — — —
Operating Income -27,57 M -19,85 M -22,90 M -19,23 M
EBITDA — — — —
R&D Expenses 18,15 M 12,92 M 15,38 M 13,23 M
SG&A Expenses — — — —
D&A — — — —
Interest Expense — — — —
Income Tax — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 31,71 M 18,61 M 19,19 M 20,41 M
Total Liabilities 13,30 M 8,89 M 6,98 M 6,19 M
Shareholders' Equity 18,41 M 9,71 M 12,20 M 14,22 M
Total Debt — — — —
Cash & Equivalents 31,63 M 18,53 M 19,13 M 19,99 M
Current Assets 31,71 M 18,61 M 19,19 M 20,41 M
Current Liabilities 13,30 M 8,89 M 6,98 M 6,19 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -8,2 -1,5
P/B 9,0 1,6
ROE % -129,4 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3

ETFs Holding This Stock
IRSIX IRSIX
0,00% weight
IIRSX IIRSX
0,00% weight
IRCIX IRCIX
0,00% weight
VVICX VVICX
0,00% weight
IRSSX IRSSX
0,00% weight